May 5, 2015
CorMedix, Inc. to Report First Quarter Financial Results on May 8, 2015
Apr 23, 2015
CorMedix Presents Data from Neutrolin® Post Marketing Surveillance Study At Two Medical Conferences
Apr 9, 2015
CorMedix Institutes Program to Reduce Neutrolin® Cost of Goods; Reports on Strategic Review Process Managed by Evercore
Mar 20, 2015
CorMedix Announces Effectiveness of Registration Statements for Shares Underlying Publicly Traded Warrants
Mar 9, 2015
CorMedix Clarifies Extension of Expiration Date for Publicly Traded Warrants
Mar 4, 2015
CorMedix Inc. Provides Multiple Strategic Business Updates
Jan 29, 2015
FDA Grants QIDP Designation to Neutrolin®, CorMedix Inc.’s Lead Product Candidate in the U.S.
Jan 15, 2015
CorMedix Inc. Receives Fast Track Designation For Neutrolin®
Dec 4, 2014
CorMedix Inc. Files Request with FDA for QIDP Designation for Neutrolin®
Dec 3, 2014
Neutrolin Label Expansion Approved in Germany
Oct 24, 2014
CorMedix Receives Approval from FDA to Initiate a Clinical Trial for Neutrolin in the US
Sep 25, 2014
CorMedix Announces FDA IND Filing for Neutrolin® in United States
Sep 19, 2014
Neutrolin Label Expansion Approved for the European Union
Aug 14, 2014
FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
Jun 23, 2014
CorMedix, Inc. Finalizes Pivotal Phase 3 Study Protocol for FDA
Jan 10, 2014
CorMedix Awarded European Patent for Neutrolin
Jan 8, 2014
CorMedix Inc. to Raise $2,000,000 in Follow on Offering
